Analysis of outcomes in resected early-stage NSCLC with rare targetable driver mutations.

Ther Adv Med Oncol · 2024 · PMC11672496 · PMID 39734710

Europe PMC DOI

hedged sentences

0.0910

closest p · 1.8× alpha

0.0910

boldest claim

The sentences

did not reach statistical significancep = 0.091so close (0.05 < p ≤ 0.1)

The difference in RFS did not reach statistical significance in stage II compared to stage I (HR 1.70, 95% CI: 0.92, 3.14; p = 0.091; Figure 2(a) ).

also in 111,027 other papers

showed a trendno p-value reported

Despite numerically poorer RFS, however, the OS of all rare mutations showed a trend to be superior to KRAS G12C-mutated NSCLC.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.